Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis.
Lasco
A
A
Department of Internal Medicine, University of Messina, A.O.U. Policlinico G. Martino Via C. Valeria, 98125, Messina, Italy.
Catalano
A
A
Morabito
N
N
Gaudio
A
A
Basile
G
G
Trifiletti
A
A
Atteritano
M
M
D000324:Adrenocorticotropic Hormone / Q000097:blood; D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000378:metabolism*; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000378:metabolism; D019379:Teriparatide / Q000494:pharmacology* / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D019379:Teriparatide; D000324:Adrenocorticotropic Hormone; D002118:Calcium; D006854:Hydrocortisone